Close

Needham & Company Starts Jazz Pharmaceuticals (JAZZ) at Buy

September 22, 2021 4:15 PM EDT Send to a Friend
Needham & Company analyst Ami Fadia initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login